Renaissance Technologies LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 76.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 300,943 shares of the medical device company’s stock after selling 961,198 shares during the period. Renaissance Technologies LLC’s holdings in DexCom were worth $45,093,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of DXCM. Jennison Associates LLC boosted its stake in shares of DexCom by 211.2% during the 2nd quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock worth $208,574,000 after acquiring an additional 944,642 shares in the last quarter. Artisan Partners Limited Partnership increased its position in shares of DexCom by 71.6% in the first quarter. Artisan Partners Limited Partnership now owns 1,164,081 shares of the medical device company’s stock worth $138,642,000 after acquiring an additional 485,519 shares in the last quarter. Geode Capital Management LLC increased its position in shares of DexCom by 17.2% in the fourth quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock worth $124,776,000 after acquiring an additional 152,781 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of DexCom by 4.6% during the first quarter. Blair William & Co. IL now owns 1,010,355 shares of the medical device company’s stock valued at $120,333,000 after acquiring an additional 44,803 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in DexCom by 3.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 438,996 shares of the medical device company’s stock valued at $65,780,000 after purchasing an additional 13,448 shares during the last quarter. Hedge funds and other institutional investors own 96.79% of the company’s stock.

In other news, EVP Jacob Steven Leach sold 5,099 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $145.32, for a total value of $740,986.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Nicholas Augustinos sold 1,208 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $146.32, for a total value of $176,754.56. The disclosure for this sale can be found here. Insiders have sold a total of 49,235 shares of company stock valued at $7,838,126 in the last quarter. Corporate insiders own 0.88% of the company’s stock.

Shares of NASDAQ:DXCM traded up $2.63 during trading on Wednesday, hitting $147.87. 17,190 shares of the company’s stock were exchanged, compared to its average volume of 895,107. DexCom, Inc. has a 1-year low of $105.05 and a 1-year high of $178.45. The firm has a 50-day moving average price of $160.12 and a two-hundred day moving average price of $139.27. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. The firm has a market cap of $13.26 billion, a P/E ratio of 492.90 and a beta of 0.72.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business had revenue of $336.40 million for the quarter, compared to analyst estimates of $304.40 million. During the same period in the prior year, the business posted ($0.10) earnings per share. DexCom’s revenue was up 38.7% compared to the same quarter last year. As a group, research analysts predict that DexCom, Inc. will post 0.94 EPS for the current year.

Several analysts have recently commented on DXCM shares. TheStreet upgraded DexCom from a “d+” rating to a “c” rating in a report on Friday, June 28th. UBS Group increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. Canaccord Genuity increased their price objective on shares of DexCom from $160.00 to $185.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Finally, Bank of America upped their target price on shares of DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Six analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. DexCom has a consensus rating of “Buy” and an average price target of $168.44.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.